(6) The number of shares of Common Stock beneficially owned includes, before giving effect of the sale of 832 shares of Common Stock by the Company on behalf of Mr. Williams to satisfy tax obligations in connection with vesting of equity awards
and not as a discretionary transaction by Mr. Williams and in each case unless as modified by the Williams Transition Agreement (as defined below): (i) 21,481 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal
installments for the period from September 20, 2024 to September 20, 2026 on each September 20th, December 20th, March 20th, and June 20th, so long as Mr. Williams remains in the service of the Company on each such date, and (ii) 39,206
RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Mr. Williams
remains in the service of the Company on each such date. Pursuant to a Transition Agreement (the “Williams Transition Agreement”) entered into on August 23, 2024 between Mr. Williams and the Company, Mr. Williams resigned from the
Company, effective November 30, 2024. Pursuant to the Williams Transition Agreement, if Mr. Williams remains employed by until and through such date and adequately fulfills his duties and responsibilities to the Company, including providing
training, information transfer and/or any other assistance reasonably requested by or on behalf of any person(s) hired and/or designated by the Company to assume any or all of his duties and responsibilities, Mr. Williams is entitled to receive the
following compensation and benefits: (a) a one-time bonus in the gross amount of $151,925, to be paid on such date, less applicable taxes and withholdings, and (b) the full, accelerated vesting of any and all restricted stock awards he has been
issued and have not vested, effective as of such date.
(7) On July 11, 2023, George Oliva resigned as the Principal Financial Officer of the Company and assumed the role of the Senior Vice President of Finance and Strategic Operations of the Company. Mr. Oliva’s last day of employment with the
Company was December 1, 2023.
6
(8) The number of shares of Common Stock beneficially owned includes (i) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from December 20, 2024 to December 20, 2027, on each
December 20th, March 20th, June 20th, and September 20th, so long as Ms. Briskey remains in the service of the Company on each such date, and (ii) 7,422 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments
for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Ms. Briskey remains in service of the Company on each such date.
(9) The number of shares of Common Stock beneficially owned includes (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Dr. Gilbert remains in the service of the Company on each such date, (ii) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the
period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Dr. Gilbert remains in the service of the Company on each such date, and (iii) 7,422 RSAs granted under the
LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Dr. Gilbert remains in service of the Company
on each such date.
(10) The number of shares of Common Stock beneficially owned includes (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Mr. Howitt remains in the service of the Company on each such date, (ii) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for
the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Mr. Howitt remains in the service of the Company on each such date, and (iii) 7,422 RSAs granted under
the LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Mr. Howitt remains in service of the
Company on each such date.
(11) The number of shares of Common Stock beneficially owned includes (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Mr. Kristensen remains in the service of the Company on each such date, (ii) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments
for the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Mr. Kristensen remains in the service of the Company on each such date, and (iii) 7,422 RSAs granted
under the LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Mr. Kristensen remains in service of
the Company on each such date.
(12) The number of shares of Common Stock beneficially owned includes (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Mr. Peruvemba remains in the service of the Company on each such date, (ii) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments
for the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Mr. Peruvemba remains in the service of the Company on each such date, and (iii) 7,422 RSAs granted
under the LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Mr. Peruvemba remains in service of
the Company on each such date.
(13) The number of shares of Common Stock beneficially owned includes (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Mr. Tobias remains in the service of the Company on each such date, (ii) 7,541 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for
the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Mr. Tobias remains in the service of the Company on each such date, and (iii) 7,422 RSAs granted under
the LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Mr. Tobias remains in service of the
Company on each such date.
(14) The number of shares of Common Stock beneficially owned consists of (i) 4,616 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for the period from September 20, 2024 to September 20, 2026 on each
September 20th, December 20th, March 20th, and June 20th, so long as Ms. Wilson remains in the service of the Company on each such date, (ii) 7,543 RSAs granted under the LTIP, which are scheduled to vest quarterly in equal installments for
the period from December 20, 2024 to December 20, 2027, on each December 20th, March 20th, June 20th, and September 20th, so long as Ms. Wilson remains in the service of the Company on each such date, and (iii) 7,424 RSAs granted under
the LTIP, which are scheduled to vest quarterly in equal installments for the period from March 15, 2024 to March 15, 2027 on each March 15th, June 15th, September 15th, and December 15th, so long as Ms. Wilson remains in service of the
Company on each such date.
(15) See the information included in footnotes 4 through 14 above.
7
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Proxy Statement and any amendment, including the sections entitled “Risk Factors”, contain “forward-looking statements” within the meaning of Section 21(E) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). These forward-looking statements, including as they relate to the potential Asset Purchase, include, without limitation: statements regarding new products or services;
statements concerning litigation or other matters; statements concerning projections, predictions, expectations, estimates or forecasts for our business, financial and operating results and future economic performance; statements of our management’s
goals and objectives; statements concerning our competitive environment, availability of resources and regulation; trends affecting our financial condition, results of operations or future prospects; our financing plans or growth strategies; statements of
the timing of the Asset Purchase; statements of the potential consummation of the Asset Purchase; and other similar expressions concerning matters that are not historical facts. Words such as “may”, “will”, “should”, “could”, “would”, “predicts”,
“potential”, “continue”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes” and “estimates,” and variations of such terms or similar expressions, are intended to identify such forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements
are based on information available at the time they are made and/or our management’s good faith belief as of that time with respect to future events. Our actual results may differ materially from those expressed in, or implied by, the forward-looking
statements due to a number of factors including, but not limited to, those set forth under the heading “Risk Factors” in this Proxy Statement, as well as other risks discussed in documents that we file with the SEC.
Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in
assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make
additional updates with respect to those or other forward-looking statements. You should review our subsequent reports filed with the SEC described in the sections of this Proxy Statement entitled “Additional Information,” all of which are accessible
on the SEC’s website at www.sec.gov.
8
SUMMARY TERM SHEET
This Summary Term Sheet provides an overview of material information regarding the proposed Asset Purchase and may not contain all of the information that is important to you. You should carefully read this entire proxy statement, including the
Asset Purchase Agreement attached as Appendix C, for a more complete understanding of the Asset Purchase and related matters.
· On September 4, 2024, the Company, entered into the Asset Purchase Agreement (the “Original Asset Purchase Agreement”) with Data Vault, as amended pursuant to that Amendment to the Asset Purchase Agreement, dated November 14, 2024
(the “APA Amendment”, and together with the Original Asset Purchase Agreement, the “Asset Purchase Agreement”), pursuant to which the Company has agreed to purchase, assume and accept from Data Vault all of the rights, title and
interests in, to and under certain assets (the “Transferred Assets”), including Data Vault’s information technology assets, certain patents, trademarks, and software source code.
· Pursuant to the Asset Purchase Agreement, the Company has agreed to acquire the Transferred Assets for an aggregate purchase price of $210,000,000 (the “Purchase Price”), which shall consist of (i) $10,000,000 payable in the form of a
promissory note issued by the Company to Data Vault, (ii) $200,000,000 in validly issued, fully paid and nonassessable shares of restricted Common Stock, which number of shares shall be 40,000,000, and is calculated based on a per share
price of $5.00 (the “Closing Stock Consideration”), and (iii) the assumption of the transferred liabilities, which clauses (i) through (iii) above, collectively, shall comprise the total consideration to be paid for the Transferred Assets. The
Company will only assume the Transferred Liabilities, if any. For more information about the transactions contemplated by the Asset Purchase Agreement, please see the section entitled “Asset Purchase.”
· The Asset Purchase Agreement includes customary representations and warranties and various customary covenants and closing conditions that are subject to certain limitations, including, without limitation, certain third-party consents and
agreements. Furthermore, pursuant to the terms of the Asset Purchase Agreement, effective at the closing, the Company has also agreed to appoint two new members to its board of directors, nominated by Data Vault, and reasonably acceptable
to the Company. For more information about the Asset Purchase Agreement, please see the section entitled “Asset Purchase—Asset Purchase Agreement.”
· Pursuant to the Asset Purchase Agreement, the Company and Data Vault shall enter into a royalty agreement (the “Royalty Agreement”), in a form to be mutually agreed between the parties, providing for the Company’s obligations to make
royalty payments to Data Vault in an amount equal to 3% of the Company’s revenue generated from or otherwise attributable to any patent rights included in the Transferred Assets, commencing as of the closing and ending upon the expiration
(on a patent-by-patent basis) of such patent rights, as further set forth in the Royalty Agreement.
· Pursuant to the Asset Purchase Agreement, the Company shall enter into an employment agreements, including a non-competition and non-solicitation agreement, mutually agreed to and signed by the Company and each key employee as of or
prior to the closing. For more information about the employment agreements, please see the section entitled “Asset Purchase—Asset Purchase Agreement.”
· The Asset Purchase Agreement may be terminated at any time prior to the consummation of the Asset Purchase upon agreement of the parties thereto. Any party can also terminate the Asset Purchase Agreement after December 31, 2024 (the
“Outside Date”), by a party by delivery of a written notice to the other party in accordance with the Asset Purchase Agreement if the Closing shall not have been consummated on or prior to 5:00 pm Eastern Time on the Outside Date. For more
information about the termination rights under the Asset Purchase Agreement, please see the section entitled “Asset Purchase—Asset Purchase Agreement.”